Immunomic Therapeutics Opens New Process Development Lab at Hershey Center for Applied Research
FOR IMMEDIATE RELEASE
/EINPresswire.com/ Hershey, PA, & Rockville, MD October 31st, 2012 - Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a privately-held biotechnology company with laboratories in Rockville, MD, and offices in Lancaster, PA announced that it has signed the lease for a new facility in the Hershey Center for Applied Research ("HCAR"). This facility will house a fermentation laboratory to support the development of ITI's LAMP-vax™ plasmid-based DNA vaccines for use in ground-breaking research & development of vaccines for allergy, infectious disease and cancer.
The new facility will be housed in the Hershey Center for Applied Research (HCAR), a cutting-edge research park located in Hershey, PA. ITI will occupy about 1700 sq ft of the 80,000 sq ft facility, built by Wexford Science and Technology, is one of several that will be strategically located in HCAR's new research park. HCAR has leveraged local resources and forged partnerships with Penn State University and the Penn State Milton S. Hershey Medical Center. The facility is newly-constructed and offers ITI customizable laboratory and office space.
ITI will be deploying Nature Technology Corporation's "HyperGRO™ DNA production process at the new laboratory. The laboratory will be under the direction of a new bio-process engineer at the facility; this yet to be hired individual will establish a plasmid process development and production laboratory with the goal of generating LAMP-vax plasmid-based vaccines for internal R&D use and to support future technical transfer of the production process of future vaccines ready for commercialization.
Immunomic Therapeutics is currently implementing LAMP in the clinic with an investigational allergy vaccine for the treatment of rhino-conjunctivitis to Japanese Red Cedar. ITI has begun an open label, Phase I, clinical study designed to establish the safety of the LAMP-vax platform. The primary objective of this Phase I Study is to evaluate both the safety and immunological response of therapeutic doses and the dosing regimen of JRC-LAMP-Vax™ vaccine as it applies to allergy patients. The study, being conducted in a clinical center based in Honolulu, HI, is expected to be complete in the winter of 2012.
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on its patented LAMP Technology platform. LAMP-vax™ vaccine technology significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com or contact Dr. Bill Hearl, President / CEO at 1-717-327-1919 or email immunomix@gmail.com
x x x
/EINPresswire.com/ Hershey, PA, & Rockville, MD October 31st, 2012 - Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a privately-held biotechnology company with laboratories in Rockville, MD, and offices in Lancaster, PA announced that it has signed the lease for a new facility in the Hershey Center for Applied Research ("HCAR"). This facility will house a fermentation laboratory to support the development of ITI's LAMP-vax™ plasmid-based DNA vaccines for use in ground-breaking research & development of vaccines for allergy, infectious disease and cancer.
The new facility will be housed in the Hershey Center for Applied Research (HCAR), a cutting-edge research park located in Hershey, PA. ITI will occupy about 1700 sq ft of the 80,000 sq ft facility, built by Wexford Science and Technology, is one of several that will be strategically located in HCAR's new research park. HCAR has leveraged local resources and forged partnerships with Penn State University and the Penn State Milton S. Hershey Medical Center. The facility is newly-constructed and offers ITI customizable laboratory and office space.
ITI will be deploying Nature Technology Corporation's "HyperGRO™ DNA production process at the new laboratory. The laboratory will be under the direction of a new bio-process engineer at the facility; this yet to be hired individual will establish a plasmid process development and production laboratory with the goal of generating LAMP-vax plasmid-based vaccines for internal R&D use and to support future technical transfer of the production process of future vaccines ready for commercialization.
Immunomic Therapeutics is currently implementing LAMP in the clinic with an investigational allergy vaccine for the treatment of rhino-conjunctivitis to Japanese Red Cedar. ITI has begun an open label, Phase I, clinical study designed to establish the safety of the LAMP-vax platform. The primary objective of this Phase I Study is to evaluate both the safety and immunological response of therapeutic doses and the dosing regimen of JRC-LAMP-Vax™ vaccine as it applies to allergy patients. The study, being conducted in a clinical center based in Honolulu, HI, is expected to be complete in the winter of 2012.
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on its patented LAMP Technology platform. LAMP-vax™ vaccine technology significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com or contact Dr. Bill Hearl, President / CEO at 1-717-327-1919 or email immunomix@gmail.com
x x x
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.